Virtu Financial LLC Acquires Shares of 10,786 Anixa Biosciences, Inc. (NASDAQ:ANIX)

Virtu Financial LLC purchased a new stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) in the third quarter, according to its most recent filing with the SEC. The fund purchased 10,786 shares of the company’s stock, valued at approximately $34,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC increased its stake in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Tyler Stone Wealth Management grew its position in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the last quarter. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the second quarter worth about $31,000. Finally, Nations Financial Group Inc. IA ADV lifted its holdings in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after acquiring an additional 7,500 shares during the last quarter. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $2.69 on Friday. The firm’s 50 day moving average is $3.19 and its two-hundred day moving average is $3.03. The firm has a market capitalization of $86.56 million, a P/E ratio of -6.90 and a beta of 0.82. Anixa Biosciences, Inc. has a 52 week low of $2.14 and a 52 week high of $5.13.

Analyst Upgrades and Downgrades

ANIX has been the subject of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.